Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Interest Receivables Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Perspective Therapeutics (CATX) Long-Term Debt Repayments (2023 - 2026)

Perspective Therapeutics' Long-Term Debt Repayments history spans 6 years, with the latest figure at $15000.0 for Q1 2026.

On a quarterly basis, Long-Term Debt Repayments rose 15.38% to $15000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $54000.0, a 10.2% increase, with the full-year FY2025 number at $52000.0, up 8.33% from a year prior.
Long-Term Debt Repayments hit $15000.0 in Q1 2026 for Perspective Therapeutics, up from $13000.0 in the prior quarter.
Over the last five years, Long-Term Debt Repayments for CATX hit a ceiling of $21000.0 in Q3 2023 and a floor of $8000.0 in Q2 2024.
Historically, Long-Term Debt Repayments has averaged $14076.9 across 4 years, with a median of $13000.0 in 2025.
Biggest five-year swings in Long-Term Debt Repayments: plummeted 60.0% in 2024 and later soared 62.5% in 2025.
Tracing CATX's Long-Term Debt Repayments over 4 years: stood at $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024, then increased by 8.33% to $13000.0 in 2025, then increased by 15.38% to $15000.0 in 2026.
Business Quant data shows Long-Term Debt Repayments for CATX at $15000.0 in Q1 2026, $13000.0 in Q4 2025, and $13000.0 in Q3 2025.